| 摘要 |
This invention relates to a composition comprising an anti-HIV treatment and a treatment for side effects of said anti-HIV treatment in an HIV-infected patient. This invention is, for example, very useful in the treatment of side effects caused by certain anti-HIV treatments, for example premature aging and lipodystrophy, which can be caused by protease inhibitors or reverse transcriptase inhibitors. The composition of this invention includes at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, at least one farnesyl-pyrophosphate synthase inhibitor, and at least one anti-HIV agent. One of the processes for treating an HIV-infected patient includes, in any order, the following steps: (i) administration of a mixture including at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and at least one farnesyl-pyrophosphate synthase inhibitor and (ii) administration of an anti-HIV agent, in which the administrations are concomitant, successive or alternative. |
| 主权项 |
1. A pharmaceutical composition, comprising:
a synergistically effective amount of the combination of at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor or one of its physiologically acceptable salts, which is selected from the group consisting of pravastatin, atorvastatin, simvastatin, rivastatin, mevastatin, velostatin, fluvastatin, cerivastatin, rosuvastatin, pitavastatin, lovastatin, and a pharmaceutically acceptable salt thereof; and at least one farnesyl-pyrophosphate synthase inhibitor or one of its physiologically acceptable salts, wherein the farnesyl-pyrophosphate synthase inhibitor is selected from the group consisting of a molecule of the aminobiphosphonate (NBP) family or one of its physiologically acceptable salts which is an aminobisphosphonate selected from the group consisting of alendronic acid or its ionic form, alendronate; ibandronic acid or its ionic form, ibandronate; neridronic acid or its ionic form, neridronate; olpadronic acid or its ionic form, olpadronate; pamidronic acid or its ionic form, pamidronate; risedronic acid or its ionic form, risedronate; zoledronic acid or its ionic form, zoledronate; 4-N,N-dimethylaminomethane diphosphonic acid or its ionic form, dimethylaminomethanediphosphonate; α-amino-(4 hydroxybenzylidene) diphosphonate; and a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition further comprises at least one anti-HIV agent, and wherein the anti-HIV agent is a protease inhibitor or a reverse transcriptase inhibitor. |
